bluuebunny/crossref_metadata_2025_split huggingface dataset:
Crystal structure of N-(3,5-benzenedicarboxy)-2,5-phenyl-3,4-(9,10-dihydroanthracen-diyl)-pyrrole—acetone—water (1:1:1), C38H25NO4 · C3H6O · H2O
Authors: Uytterhoeven K. , Van Meervelt L. , Smet M. , Dehaen W. 
Published: September 2014

Abstract C41H33NO6, triclinic, P1̅ (No. 2), a = 9.610(3) Å, b = 12.877(3) Å, c = 15.138(4) Å, α = 109.29(2)°, β = 105.16(2)°, γ = 94.24(2)°, V = 1680.0 Å3, Z = 2, Rgt(F) = 0.059, wRref(F2) = 0.161, T = 289 K.
Crystal structure of diethylenetriammonium silver(I) di(4-nitrobenzoate) monohydrate, [Ag(C4H14N3)](C7H4NO4)2 · H2O
Authors: Zhu H.-L. , Shao S.-C. , Yang S. , Qiu X.-Y. , Ma J.-L. , Fun H.-K. 
Published: September 2014

Abstract C18H24AgN5O9, monoclinic, P121/n1 (No. 14), a = 6.2181(3) Å, b = 26.975(2) Å, c = 13.1982(7) Å, β = 99.648(2)°, V = 2182.5 Å3, Z = 4, Rgt(F) = 0.038, wRref(F2) = 0.082, T = 293 K.
Crystal structure of di(4-aminopyridine)silver(I) trifluoromethylsulfate, Ag(C5H6N2)2(CF3SO3)
Authors: Zhu H.-L. , Zhang M. , Sun Z.-Y. , Rong N.-N. , Zhang B. , Li Y. , Fun H.-K. 
Published: September 2014

Abstract C11H12AgF3N4O3S, monoclinic, P121/n1 (No. 14), a = 6.901(1) Å, b = 11.106(2) Å, c = 20.958(4) Å, β = 94.799(3)°, V = 1600.6 Å3, Z = 4, Rgt(F) = 0.033, wRref(F2) = 0.081, T = 293 K.
Crystal structure of (aqua)(benzimidazole-N)bis(2,4-pentanedionato-O,O′)cobalt(II), C17H22CoN2O5
Authors: Lin H. , Feng Y.-L. 
Published: September 2014

Abstract C17H22CoN2O5, orthorhombic, Pnma (No. 62), a = 7.944(2) Å, b = 14.346(3) Å, c = 16.544(3) Å, V = 1885.5 Å3, Z = 4, Rgt(F) = 0.044, wRref(F2) = 0.123, T = 293 K.
Crystal structure of 2-dimethoxy-phosphinyl-1,3-benzodithiole, (C6H4S2CH)PO(OCH3)2
Authors: Xu F.-Y. , Zhang F.-S. , Wang R.-J. , Pu S.-Z. , Zhou X.-H. , Sun F. , Yuan P. 
Published: September 2014

Abstract C9H11O3PS2, monoclinic, P121/n1 (No. 14), a = 9.791(3) Å, b = 10.943(2) Å, c = 11.619(3) Å, β = 108.970(2)°, V = 1177.3 Å3, Z = 4, Rgt(F) = 0.035, wRref(F2) = 0.078, T = 293 K.
Crystal structure of 4,5-bis(2′-cyanoethylthio)-1,3-dithiole-2-thione, C9H8N2S5
Authors: Yu W.-T. , Xue G. , Fang Q. , Liu G.-Q. 
Published: September 2014

Abstract C9H8N2S5, monoclinic, P121/n1 (No. 14), a = 9.070(5) Å, b = 27.123(5) Å, c = 10.736(5) Å, β = 104.461(5)°, V = 2557.5 Å3, Z = 8, Rgt(F) = 0.038, wRref(F2) = 0.086, T = 293 K.
Crystal structure of 4-N-phenylisoindolinone, C14H11NO
Authors: Polamo M. , Talja M. 
Published: September 2014

Abstract C14H11NO, monoclinic, P121/n1 (No. 14), a = 5.925(4) Å, b = 7.556(2) Å, c = 23.11(1) Å, β = 94.67(5)°, V = 1031.3 Å3, Z = 4, Rgt(F) = 0.055, wRref(F2) = 0.140, T = 193 K.
Crystal structure of 4,7-dibromo-2,1,3-benzothiadiazole, C6H2Br2N2S
Authors: Tomura M. , Yamashita Y. 
Published: September 2014

Abstract C6H2Br2N2S, monoclinic, P121/c1 (No. 14), a = 18.3670(9) Å, b = 3.9522(2) Å, c = 22.120(2) Å, β = 97.390(6)°, V = 1592.4 Å3, Z = 8, Rgt(F) = 0.045, wRref(F2) = 0.127, T = 296 K.
Crystal structure of 1-benzoyl-2-picoloyl-hydrazine nickel(II)–methylene chloride solvate (1:0.25), Ni[OC(C6H5)NHN(C5H4N)CO)]2 · 0.25CH2Cl2
Authors: Dieng M. , Gaye M. , Sall A. S. , Welter R. 
Published: September 2014

Abstract C26.25H20.5Cl0.5NiN6O4, monoclinic, C12/c1 (no. 15), a = 25.707(1) Å, b = 14.768(1) Å, c = 18.312(1) Å, β = 132.30(5)°, V = 5142.1 Å3, Z = 8, Rgt(F) = 0.060, wRref(F2) = 0.176, T = 173 K.
Crystal structure of (2-aminopyrimidine)-(pyridine-2,6-dicarboxylato)- copper(II) trihydrate, Cu(C4H5N3)(C7H3NO4) · 3H2O
Authors: Altin E. , Kirchmaier R. , Lentz A. 
Published: September 2014

AbstractC11H14CuN4O7, triclinic, P1̅ (no. 2), a = 7.522(2) Å, b = 9.754(3) Å, c = 11.349(3) Å, α = 108.87(3)°, β = 96.53(3)°, γ = 111.55(3)°, V = 706.8 Å3, Z = 2, Rgt(F) = 0.027, wRref(F2) = 0.063, T = 293 K.
Crystal structure of (4SR,4aSR)-1-acetyl-4-hydroxy-4,8-dimethyl-1,2,3,4, 4a,7-hexahydroquinoline, C13H19NO2
Authors: Gross S. , Brüdgam I. , Hartl H. , Reißig H.-U. 
Published: September 2014

Abstract C13H19NO2, monoclinic, P121/c1 (no. 14), a = 8.399(2) Å, b = 17.386(5) Å, c = 9.043(2) Å, β = 113.872(4)°, V = 1207.6 Å3, Z = 4, Rgt(F) = 0.054, wRref(F2) = 0.167, T = 213 K.
Crystal structure of N,N′,N′′-tris(2-pyridinyl)phosphoric triamide, (NC5H4NH)3PO
Authors: Gholivand K. , Alavi M. D. , Pourayoubi M. 
Published: September 2014

Abstract C15H15N6OP, monoclinic, P121/n1 (no. 14), a = 10.558(2) Å, b = 13.448(2) Å, c = 21.814(4) Å, β = 92.314(4)°, V = 3094.6 Å3, Z = 8, Rgt(F) = 0.051, wRref(F2) = 0.101, T = 120 K.
Crystal structure of diaqua-bis(pyrazole)-μ2-squarato(1,3)nickel(II), Ni(C4O4)(C3H4N2)2(H2O)2
Authors: Kirchmaier R. , Altin E. , Lentz A. 
Published: September 2014

Abstract C10H12N4NiO6, orthorhombic, Pbca (no. 61), a = 11.890(3) Å, b = 7.909(2) Å, c = 14.664(4) Å, V = 1378.9 Å3, Z = 4, Rgt(F) = 0.028, wRref(F2) = 0.068, T = 293 K.
Crystal structure of sulfatobis{2-[N-(2-hydroxyethylaminoethyl)iminomethyl] phenolatozinc(II)}, [(ZnC11H15N2O2)2SO4]
Authors: Qiu X.-Y. , Liu Q.-X. , Wang Z.-G. , Lin Y.-S. , Zeng W.-J. , Fun H.-K. , Zhu H.-L. 
Published: September 2014

Abstract C22H30N4O8SZn2, monoclinic, P121/c1 (no. 14), a = 8.2666(6) Å, b = 23.229(2) Å, c = 13.7531(9) Å, β = 102.329(1)°, V = 2580.1 Å3, Z = 4, Rgt(F) = 0.050, wRref(F2) = 0.114, T = 293 K.
Crystal structure of bis(4-aminopyridine)silver(I) bis(3-nitrobenzoato)- silver(I) dihydrate, Ag(C5H6N2)2[Ag(C7H4NO4)2] · 2H2O
Authors: Ma J.-L. , Zou Y. , Meng F.-J. , Lin Y.-S. , Wang Z.-G. , Zhu H.-L. 
Published: September 2014

Abstract C24H24Ag2N6O10, triclinic, P1̅ (no. 2), a = 3.807(3) Å, b = 11.55(1) Å, c = 16.21(1) Å, α = 74.17(1)°, β = 84.75(1)°, γ = 89.89(1)°, V = 682.6 Å3, Z = 1, Rgt(F) = 0.045, wRref(F2) = 0.153, T = 293 K.
Crystal structure of {1-benzyl-2-[(4-nitrobenzyl)sulfanyl]-1H-imidazol-5-yl}- methanol, C18H17N3O3S
Authors: Ramazani A. , Marandi F. , Souldozi A. , Jalilian A. R. 
Published: September 2014

Abstract C18H17N3O3S, monoclinic, P121/c1 (no. 14), a = 15.705(2) Å, b = 12.083(2) Å, c = 9.368(1) Å, β = 102.404(3)°, V = 1736.3 Å3, Z = 4, Rgt(F) = 0.078, wRref(F2) = 0.226, T = 120 K.
Crystal structure of dimethyl 1,1-diacetyl-8a-hydroxy-8-oxo-1,2,8,8a-tetrahydrocyclopenta[ a]indene-2,3-dicarboxylate, C20H18O8
Authors: Ramazani A. 
Published: September 2014

Abstract C20H18O8, orthorhombic, Fdd2 (no. 43), a = 19.060(4) Å, b = 35.937(7) Å, c = 10.571(2) Å, V = 7240.6 Å3, Z = 16, Rgt(F) = 0.056, wRref(F2) = 0.139, T = 110 K.
Crystal structure of chlorodimethyl(2-aminoethanethiolato)tin(IV), (NH2CH2CH2S)SnCl(CH3)2
Authors: Couce M. D. , Faraglia G. , Russo U. , Graziani R. , Valle G. 
Published: September 2014

Abstract C4H12ClNSSn, orthorhombic, Pbca (no. 61), a = 11.422(2) Å, b = 11.475(2) Å, c = 13.582(2) Å, V = 1780.2 Å3, Z = 8, Rgt(F) = 0.057, wRref(F2) = 0.147, T = 293 K.
Crystal structure of (η4-norborna-2,5-dien)-(1,2-bis((R,R)-2,5-bis- (methoxymethyl)phospholanyl)benzene)rhodium(I) tetrafluoroborate, [Rh(C22H36O4P2)(C7H8)](BF4)
Authors: Holz J. , Börner A. , Spannenberg A. , Pribbenow C. , Heller D. , Drexler H.-J. 
Published: September 2014

Abstract C29H44BF4O4P2Rh, monoclinic, P21 (no. 4), a = 10.119(2) Å, b = 14.125(3) Å, c = 11.542(2) Å, β = 106.87(3)°, V = 1578.7 Å3, Z = 2, Rgt(F) = 0.034, wRref(F2) = 0.090, T = 200 K.
Refinement of the crystal structure of diniobium trisoxydisulfate hydrate, Nb2O3(SO4)2 · 0.25H2O
Authors: Ewald B. , Prots Yu. , Boström M. 
Published: September 2014

Abstract H0.5Nb2O11.25S2, trigonal, R3̅ (no. 148), a = 10.378(2) Å, c = 26.540(5) Å, V = 2475.7 Å3, Z = 24, Rgt(F) = 0.031, wRref(F2) = 0.072, T = 295 K.
Crystal structure of dirubidium aquapentachlorochromate(III), Rb2[CrCl5(H2O)]
Authors: Mi J.-X. , Zhou X. , Zhang H. , Mao S.-Y. , Zhao J.-T. 
Published: September 2014

Abstract Cl5CrH2ORb2, orthorhombic, Pnma (no. 62), a = 13.8123(5) Å, b = 9.7705(4) Å, c = 7.1522(4) Å, V = 965.2 Å3, Z = 4, Rgt(F) = 0.038, wRref(F2) = 0.073, T = 295 K.
Crystal structure of (diphenylphosphinoyl)phenylmethanol, C19H17O2P
Authors: Lan K. , Chen X.-L. 
Published: September 2014

AbstractC19H17O2P, monoclinic, P121/n1 (no. 14), a = 11.239(4) Å, b = 6.310(2) Å, c = 22.157(8) Å, β = 92.091(7)°, V = 1570.3Å3, Z = 4, Rgt(F) = 0.041, wRref(F2) = 0.114, T = 293 K.
Crystal structure of trans-dichloro-1,3-propanediamine-bis[(2-methoxyethyl) diphenylphosphine]ruthenium(II), RuCl2(C3H10N2)(C15H17OP)2
Authors: Warad I. , Al-Resayes S. , Eichele K. 
Published: September 2014

Abstract C33H44Cl2N2O2P2Ru, monoclinic, P121/c1 (no. 14), a = 13.278(1) Å, b = 10.315(1) Å, c = 24.825(3) Å, β = 90.340(8)°, V = 3400.1 Å3, Z = 4, Rgt(F) = 0.023, wRref(F2) = 0.059, T = 173 K.
Crystal structure of bis(N-(2-aminoethyl)salicylaldiminato)iron(III) isothiocyanide, [Fe(C9H11N2O)2][NCS]
Authors: Feng X. , Han X. , Wang L.-Y. 
Published: September 2014

Abstract C19H22FeN5O2S, triclinic, P1̅ (no. 2), a = 9.613(1) Å, b = 9.913(1) Å, c = 10.869(2) Å, α = 84.958(2)°, β = 89.047(2)°, γ = 86.098(1)°, V = 1029.3 Å3, Z = 2, Rgt(F) = 0.038, wRref(F2) = 0.099, T = 291 K.
Crystal structure of ethanolammonium dioxo-(N-(2-ethanolato)- 2-oxy-3-methoxybenzaldiminato-O,N,O′)vanadate(V), (NH3CH2CH2OH)[VO2{(C6H4(OCH3)(O)CHNCCH2CH2O}]
Authors: Feng J.-N. , Zhou Y.-Z. , Zhu H.-J. , Tu S.-J. 
Published: September 2014

Abstract C12H19N2O6V, monoclinic, P121/c1 (no. 14), a = 8.986(2) Å, b = 13.168(2) Å, c = 13.243(2) Å, β = 108.677(2)°, V = 1484.6 Å3, Z = 4, Rgt(F) = 0.031, wRref(F2) = 0.083, T = 294 K.
Crystal structure of rel-(3aR,6aS)-6-methyl-3,6a-diphenyl-3a,4,6,6atetrahydro- isoxazolo[5,4-c]isoxazole, C17H16N2O2
Authors: Frey W. , Shiva S. , Jäger V. 
Published: September 2014

Abstract C17H16N2O2, orthorhombic, Pca21 (no. 29), a = 5.6406(8) Å, b = 30.292(4) Å, c = 16.925(3) Å, V = 2891.9 Å3, Z = 8, Rgt(F) = 0.084, wRref(F2) = 0.236, T = 293 K.
Crystal structure of (phenanthroline-N,N′)-N-carbamoylmethyl-iminodiacetato- copper(II) dihydrate, [Cu(C6H8N2)(C12H8N2)] · 2H2O
Authors: Cheng M.-Q. , Ma L.-F. , Wang L.-Y. 
Published: September 2014

Abstract C18H20CuN4O7, monoclinic, P121/c1 (no. 14), a = 8.802(1) Å, b = 22.493(3) Å, c = 9.885(1) Å, β = 97.163(2)°, V = 1941.8Å3, Z = 4, Rgt(F) = 0.033, wRref(F2) = 0.096, T = 291 K.
Crystal structure of pentamethylpyrylium triiodide, [(CH3)5C5O][I3]
Authors: Guo S. , Hauptmann R. , Beyer C. , Kollmann T. , Schneider J. J. 
Published: September 2014

Abstract C10H15I3O, orthorhombic, Pnma (no. 62), a = 13.750(3) Å, b = 7.288(2) Å, c = 15.140(3) Å, V = 1517.2 Å3, Z = 4, Rgt(F) = 0.031, wRref(F2) = 0.071, T = 150 K.
Crystal structure of aquabis(acrylato-O,O')(1,10-phenanthroline-N,N′)- cadmium(II), Cd(H2O)(C3H3O2)2(C12H10N2)
Authors: Cai T.-J. , Jiang W.-J. , Peng Z.-S. , Long Y.-F. , Deng Q. 
Published: September 2014

Abstract C18H15CdN2O5, monoclinic, P121/n1 (no. 14), a = 9.9973(5) Å, b = 9.0433(4) Å, c = 19.4849(8) Å, β = 101.235(2)°, V = 1727.9 Å3, Z = 4, Rgt(F) = 0.025, wRref(F2) = 0.065, T = 273 K.
Crystal structure of bis(acetato-O,O′)bis(μ-acetato-O,O′)bis(κ3N-antipyrine- O]tetraoxodiuranium, U2O4(CH3COO)4[C6H5N2C3(CH3)2HO]2
Authors: Bekaert A. , Lemoine P. , Brion J. D. , Viossat B. 
Published: September 2014

Abstract C30H36N4O14U2, triclinic, P1̅ (no. 2), a = 8.989(9) Å, b = 9.709(3) Å, c = 12.22(1) Å, α = 112.94(5)°, β = 92.84(7)°, γ = 110.61(8)°, V = 897.5 Å3, Z = 1, Rgt(F) = 0.043, wRref(F2) = 0.120, T = 293 K.
Crystal structure of 1-(2-bromoethyl)-2-methyl-5-nitroimidazole, C6H8BrN3O2
Authors: Balliano T. L. , Pereira M. A. , De Simone C. A. , Malta V. R. S. , Velasquez N. , Cioletti A. G , Goulart M. O. F. 
Published: September 2014

Abstract C6H8BrN3O2, monoclinic, P121/a1 (no. 14), a = 6.3952(2) Å, b = 11.1267(3) Å, c = 12.0785(4) Å, β = 97.274(2)°, V = 852.6 Å3, Z = 4, Rgt(F) = 0.047, wRref(F2) = 0.128, T = 293 K.
Crystal structure of bis[N-cyclopropyl-5-nitrosalicylaldiminato]copper(II), Cu[(C3H5NCH)(O)C6H3(NO2)]2
Authors: Han X.-Q. , Yue G.-R. 
Published: September 2014

Abstract C20H18CuN4O6, monoclinic, P121/c1 (no. 14), a = 11.365(1) Å, b = 16.863(2) Å, c = 11.257(1) Å, β = 113.223(1)°, V = 1982.6 Å3, Z = 4, Rgt(F) = 0.035, wRref(F2) = 0.083, T = 298 K.
The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice
Authors: Schwarz P , Body J J , Cáp J , Hofbauer L C , Farouk M , Gessl A , Kuhn J M , Marcocci C , Mattin C , Muñoz Torres M , Payer J , Van De Ven A , Yavropoulou M , Selby P 
Published: September 2014

ObjectiveMedical management of primary hyperparathyroidism (PHPT) is important in patients for whom surgery is inappropriate. We aimed to describe clinical profiles of adults with PHPT receiving cinacalcet.DesignA descriptive, prospective, observational study in hospital and specialist care centres.MethodsFor patients with PHPT, aged 23–92 years, starting cinacalcet treatment for the first time, information was collected on dosing pattern, biochemistry and adverse drug reactions (ADRs). Initial cinacalcet dosage and subsequent dose changes were at the investigator's discretion.ResultsOf 303 evaluable patients with PHPT, 134 (44%) had symptoms at diagnosis (mostly bone pain (58) or renal stones (50)). Mean albumin-corrected serum calcium (ACSC) at baseline was 11.4 mg/dl (2.9 mmol/l). The reasons for prescribing cinacalcet included: surgery deemed inappropriate (35%), patient declined surgery (28%) and surgery failed or contraindicated (22%). Mean cinacalcet dose was 43.9 mg/day (s.d., 15.8) at treatment start and 51.3 mg/day (31.8) at month 12; 219 (72%) patients completed 12 months treatment. The main reason for cinacalcet discontinuation was parathyroidectomy (40; 13%). At 3, 6 and 12 months from the start of treatment, 63, 69 and 71% of patients, respectively, had an ACSC of ≤10.3 mg/dl vs 9.9% at baseline. Reductions from baseline in ACSC of ≥1 mg/dl were seen in 56, 63 and 60% of patients respectively. ADRs were reported in 81 patients (27%), most commonly nausea. A total of 7.6% of patients discontinued cinacalcet due to ADRs.ConclusionsReductions in calcium levels of ≥1 mg/dl was observed in 60% of patients 12 months after initiation of cinacalcet, without notable safety concerns.
Antiprogestins in gynecological diseases
Authors: Goyeneche Alicia A , Telleria Carlos M 
Published: September 2014

Antiprogestins constitute a group of compounds, developed since the early 1980s, that bind progesterone receptors with different affinities. The first clinical uses for antiprogestins were in reproductive medicine, e.g., menstrual regulation, emergency contraception, and termination of early pregnancies. These initial applications, however, belied the capacity for these compounds to interfere with cell growth. Within the context of gynecological diseases, antiprogestins can block the growth of and kill gynecological-related cancer cells, such as those originating in the breast, ovary, endometrium, and cervix. They can also interrupt the excessive growth of cells giving rise to benign gynecological diseases such as endometriosis and leiomyomata (uterine fibroids). In this article, we present a review of the literature providing support for the antigrowth activity that antiprogestins impose on cells in various gynecological diseases. We also provide a summary of the cellular and molecular mechanisms reported for these compounds that lead to cell growth inhibition and death. The preclinical knowledge gained during the past few years provides robust evidence to encourage the use of antiprogestins in order to alleviate the burden of gynecological diseases, either as monotherapies or as adjuvants of other therapies with the perspective of allowing for long-term treatments with tolerable side effects. The key to the clinical success of antiprogestins in this field probably lies in selecting those patients who will benefit from this therapy. This can be achieved by defining the genetic makeup required – within each particular gynecological disease – for attaining an objective response to antiprogestin-driven growth inhibition therapy.Free Spanish abstractA Spanish translation of this abstract is freely available athttp://www.reproduction-online.org/content/149/1/R15/suppl/DC1.
Nanostructure Fabrication Using Pulsed Lasers and Near-field Optical Properties of Sub-micron Particles
Authors: Zhang L. , Lu Y. F. , Song W. D. , Zheng Y. W. , Luk'yanchuk B. S. 
Published: September 2014

ABSTRACTRecently, the field of nanoelectonics has evolved into a major area of investigation. In this paper, we present a novel method of nanofabrication using pulsed lasers and near-field optical properties of sub-micron particles. For this purpose, spherical silica particles were deposited on a silicon surface. After laser illumination, hillocks with size of about 150 nm were obtained at the original position of the particles. The mechanism can be explained as the enhancement of light intensity near the contact area. Since the characteristic distance between particles and substrate is smaller than the radiation wavelength and the particle size is of the order of a wavelength, particle does not simply play the role of microfocusing lens as in far-field, but possess optical resonance effect in near-field. In our work, the light intensity on the surface under the spherical particle was calculated by solving the electromagnetic boundary problem “particle on suface”.
Universal Humanism – A Globalization Context is the Classroom of Unheard Options how to Become More Human
Authors: Svetelj Tone 
Published: September 2014

Within the context of multi-cultural and multi-religious society, embedded in the process of globalization, a traditional understanding of humanism offers insufficient frameworks for an adequate comprehension of human flourishing and human search for meaning. In addition, modernity frames and evaluates in many aspects insufficiently the incomparable worth of the human person.This article offers some guidelines for further philosophical, theological and pedagogical reflection on a humanism that is more suitable for our life in the process of globalization and modernity. Such humanism continually moves us toward a better comprehension of what “human” means within a universe of divergent cultures, religions, traditions, and races. This humanism is called universal humanism, based on the Greek word kaqolou , comprising both universality and wholeness. The first part of this article analyzes some of the main characteristics of humanism in the Greek and Roman contexts, which provide historical and theoretical frameworks for universal humanism. The second part justifies the relevance and usefulness of such humanism: it helps us to transcend singular cultures, nations, political systems, religions, and, by default, to discover or explore anew the meaning of the human person on a global level. The last part of this article suggests some pedagogical attitudes that will help us to embrace and remain in a dialogical relationship with all of humanity, in order to enrich our comprehension of the incomparable worth of the human person, this time from a universal perspective.
Caritas in Veritate – Love and Truth an Implication of a Good Society
Authors: Młyński Józef 
Published: September 2014

Love and truth are the two attributes of a well-functioning society. Unfortunately, these two basic values are often being devalued in the modern world. The reason for this is the lack of a sense of justice. Especially because in the social and cultural context the truth is often relativized. In this context it is worth analysing the Pope Benedict XVI’s encyclical Caritas in Veritate , in which one should pay attention to a construction of the society in which today’s human person lives.Love and truth are the two attributes of a good society in with each human is equipped. From the very beginning, the human person is called to be directed by love and truth. He or she is called to this truth by his or her Christian life and ontic dimension of his or her nature. Society without love and truth will be threatened with agony, because it will not only stop developing but also its wrongly understood economical status will become a road to nowhere. That is why we should definitely accept the thesis that homo economicus must convert into homo religiosus in the name of love and truth, so that society will be good. Let love in truth leads to a good society, which the whole world is for us.
Non-verbal Communication and Communicative Understanding of the Liturgy and Liturgical Signs in the Light of Charles Sanders Peirce’s Theory of Signs
Authors: Krajnc Slavko , Gerjolj Stanko 
Published: September 2014

The human person as a “triadic” creature needs ritual at all three levels − physical, psychological and spiritual − of his or her being. At the physical level, ritual serves as support for a healthier life-style. At the psychological level, ritual regulates intrapersonal and interpersonal communicatio. At the level of spirituality, it places him or her in the context of transcendence and “recent aims” and both individually and communally gives meaning to human life. Therefore, the author of the paper first This paper starts by considering the human person as a ritual creature that already with his body requires certain ritual acts and various forms of nonverbal communication. In the central part of the discussion, the author focuses on Peirce’s theory of signs and presents it as one model suitable for understanding and explaining liturgical signs. This is an interesting understanding of religious signs, which encourages an interpretative relationship between the human person and the liturgy, its signs and contents.
Research in the tension between measuring the educational status quo and a pedagogical realization of a vision – demonstrated by the example of orientation concerning the life, value and sense of adolescents with regard to the implementation of inclusion
Authors: Feiner Franz 
Published: September 2014

In the article, the current KPH Graz Jugendwertestudie is displayed:In the historical development process, as a research from the „Firmungsstudie” to the intercultural and inter-religious Values StudyClassified in an interdisciplinary question, namely the sense and value of lifeTolerance was established as a fundamental value regarding the studyThe “more” of “tolerance”, namely the “acceptance” from the religions, for example the Islam in terms of the “Projekt Weltethos” (project world ethos) (H. Küng), where all religions shall use their ethical potential for the world’s future.The learning of empathy and solidarity is viewed in an European dimension and is based on the vision of a worldwide inclusive society and a concretization of “steps into the future” is indicated too. The current European research project ETHOS has investigated the needs of all stakeholders (children, students, teachers, parents) and has developed holistic pedagogical-didactic materials for the age group of 3 to 15.The inspiring principles of the Catholic Social Doctrine as a major impetus towards a “planetarischen Bewusstseins“ (planetary consciousness) (L. Boff) are going to be included, where we see ourselves as “citizens of the world” and can understand and help to form a new, more inclusive society.
Theological Reflection on Tourism and Leisure
Authors: Ostrowski Maciej 
Published: September 2014

Tourism is one of the most popular leisure activities. In this article we intend to point out a few elements that may constitute the founding blocks of a theology of leisure and a theology of tourism: a theology of time, a theology of freedom, a theology of creation, a theology of leisure, a theology of joy, a theology of the journey (homo viator, homo peregrinus). There are many points both in the Bible and in the teachings of the Church that leave room for the development of this notion. According to the Second Vatican Council, tourism is classified as one of the contemporary phenomena which can be described as one of the signs of time. The Council recommends individuals and groups to study them carefully and incorporate them in the general context of pastoral work.